GENE ONLINE|News &
Caris Life Sciences Authorizes Common Stock Repurchase Program
Caris Life Sciences announced a share repurchase program on Monday, June 8, 2026, authorizing the company to buy back a portion of its outstanding common stock. The board of directors approved the initiative, which allows the firm to acquire shares through open market transactions or privately negotiated deals depending on prevailing market conditions and other corporate factors.
The company intends to fund the repurchases using its existing cash reserves. This program does not obligate Caris Life Sciences to acquire any specific number of shares, and the board retains the authority to suspend or terminate the buyback activity at any time without prior notice. The timing and total volume of the repurchases will depend on the company’s assessment of its stock price, general economic conditions, and alternative investment opportunities available to the business.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: June 8, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
PYGO2 Overexpression Linked to Increased Plasma Cell Proliferation in Multiple Myeloma Patients with 1q21 Amplification
2026-07-10
Sean Kaufman Faces Senate Scrutiny Over Past Vaccine Safety Comments Ahead of Confirmation Hearing
2026-07-10
IBEC and European Researchers Receive Novo Nordisk Foundation Grant to Study Physics of Living Matter
2026-07-10
Manufacturers Integrate Commercial, Government, and Cash-Pay Strategies to Optimize Product Life Cycle Value
2026-07-10
EVENT
2026-08-07
Healthy Ageing Tech Show (7-9 Aug, TAIPEI WTC) (Longevity, elder care & ageing tech)
Taipei, Taiwan
